ArticleScientific reports2025
Bioactive aporphines and flavonoids from a fermented beverage target metabolic inflammatory pathways in obesity and type 2 diabetes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The global syndemic of obesity and type 2 diabetes (T2D) demands safe, multi-targeted dietary interventions. FH03FS, a sterilized fermented beverage blended from five medicinal food homologous (MFH) plants, represents a promising candidate. However, the phytochemical profile and mechanistic basis for its potential efficacy remain uncharacterized. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis of FH03FS revealed a wide spectrum of compounds. Ten key bioactive ingredients, primarily aporphines and flavonoids, were identified as the primary active components based on favorable pharmacokinetic properties. In silico Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiling indicated high gastrointestinal (GI) absorption and low toxicity risks for these compounds. Network pharmacology demonstrated the modulation of core pathways driving metabolic inflammation. Molecular docking preliminarily identified multiple high-affinity interactions between the bioactive compounds and core targets. The exceptional stability and strong binding of representative complexes, notably Morin-ESR1 and Asimilobine-PPARG, were further validated by molecular dynamics (MD) simulations. This study demonstrates that FH03FS, rich in aporphines and flavonoids, exerts multi-target effects against obesity and T2D. Our findings thereby provide a phytochemical and mechanistic foundation for its development as a ready-to-consume functional beverage and offer testable hypotheses for future validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.